Showing results (121-130 of 178) with videos related to

Sort By:
Pageof 18
Transfusion|June 7, 2005
Microbial contamination of hematopoietic progenitor cell grafts-incidence, clinical outcome, and cost-effectiveness: an analysis of 735 graftsRammurti Kamble, Shubham Pant, George B Selby, et al.
Antimicrobial Agents and Chemotherapy|November 29, 2017
Azithromycin Pharmacodynamics against Persistent Haemophilus influenzae in Chronic Obstructive Pulmonary DiseaseBrian T Tsuji, James Fisher, Raheal Boadi-Yeboah, et al.
COPD|October 4, 2014
C-Reactive Protein at Discharge, Diabetes Mellitus and ≥ 1 Hospitalization During Previous Year Predict Early Readmission in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary DiseaseErnesto Crisafulli, Antoni Torres, Arturo Huerta, et al.
International Journal of Chronic Obstructive Pulmonary Disease|May 8, 2023
Healthcare Resource Utilization, Cost and Clinical Outcomes in Patients Diagnosed with COPD Initiating Tiotropium Bromide/Olodaterol versus Fluticasone Furoate/Umeclidinium/Vilanterol Based on Exacerbation HistorySanjay Sethi, Brendan Clark, Lindsay G S Bengtson, et al.
Data in Brief|September 20, 2019
Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary diseaseJames Donohue, Edward Kerwin, Sanjay Sethi, et al.
Infection and Immunity|August 6, 2008
Serial isolates of persistent Haemophilus influenzae in patients with chronic obstructive pulmonary disease express diminishing quantities of the HMW1 and HMW2 adhesinsDeborah M Cholon, David Cutter, Stephen K Richardson, et al.
Plos One|September 5, 2025
Leveraging dynamic stability to infer regulation in protein-protein interaction networks: A study of infectious vulnerability in COPDJoyce Reimer, Jeffrey Page, Pranta Saha, et al.
COPD|August 2, 2008
COPD as a lung disease with systemic consequences--clinical impact, mechanisms, and potential for early interventionMarc Decramer, Stephen Rennard, Thierry Troosters, et al.
International Journal of Chronic Obstructive Pulmonary Disease|April 10, 2019
AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPDSanjay Sethi, Edward Kerwin, Henrik Watz, et al.
Respiratory Medicine|June 1, 2019
Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary diseaseJames F Donohue, Edward Kerwin, Sanjay Sethi, et al.
Pageof 18